Aligos Therapeutics (ALGS) announced the appointment of Ramon Polo as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. He joins Aligos from Shionogi Inc., where he served as the Senior Vice President, Head of Global Regulatory Affairs, and focused on regulatory strategies for a number of different Therapeutic Areas, including infectious diseases.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics: Promising Advancements in HBV Treatment and Strategic Pipeline Growth
- Aligos Therapeutics assumed with a Buy at H.C. Wainwright
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study
- Aligos Therapeutics Reports Q2 2025 Progress and Results